Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apremilast for RAS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03690544
Recruitment Status : Active, not recruiting
First Posted : October 1, 2018
Last Update Posted : December 17, 2020
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
Alison J. Bruce, Mayo Clinic

Brief Summary:
Determination of treatment efficacy and safety of Apremilast in patients with RAS

Condition or disease Intervention/treatment Phase
Recurrent Aphthous Stomatitis Drug: Apremilast 30mg Early Phase 1

Detailed Description:

The study will be a pilot study using apremilast 30mg orally twice daily, for treatment of RAS in males and females between 18 and 70 years old.

Subjects will be recruited from the clinical practice of the Department of Dermatology or Division of Rheumatology at Mayo Clinic Florida. Fifteen males and females with RAS will be enrolled.

The study will consist of 3 phases: a screening phase, a 16 week treatment phase and an 8 week posttreatment observational follow-up phase.

The screening phase will consist of: obtaining informed consent, demographic information, medical history, inclusion and exclusion criteria, prior and concomitant medication use, adverse events; collecting vital signs and weight; performing complete physical examination and limited physical examination; obtaining hematology, serum chemistry, urinalysis, pregnancy test and providing contraception education.

During the 16-week treatment phase, all subjects receive apremilast.

All subjects who complete the active treatment phase are to enter the 8-week posttreatment observational follow-up phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Apremilast 30mg orally twice daily for 16 weeks
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)
Actual Study Start Date : October 12, 2018
Estimated Primary Completion Date : March 1, 2021
Estimated Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Canker Sores
Drug Information available for: Apremilast

Arm Intervention/treatment
Experimental: Single Arm
Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
Drug: Apremilast 30mg
Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.




Primary Outcome Measures :
  1. Improvement in duration of RAS lesions [ Time Frame: up to 24 weeks ]
    Improvement in the duration of oral ulcers will be used to factor the improvement of RAS lesions.

  2. Percentage change in number of RAS lesions [ Time Frame: up to 24 weeks ]
    The percentage change in the number of oral ulcers will be used to factor the improvement of RAS lesions.

  3. Improvement in duration of the remission period between ulcer episodes [ Time Frame: up to 24 weeks ]
    Improvement in duration of the remission period between ulcer episodes will be used to factor the improvement of RAS lesions.


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 24 weeks ]
    Type, frequency, severity and relationship of the adverse events to apremilast will be assessed and reported.

  2. Discontinuation of study participants [ Time Frame: 24 weeks ]
    Number of sbjects who prematurely discontinue treatment with apremilast due to any adverse event.

  3. Frequency of clinically significant changes in vital signs and/or laboratory findings [ Time Frame: 24 weeks ]
    The frequency of clinically significant changes in vital signs and/or laboratory findings will be measured through a complete physical examination using physiological parameters, as well as hematology and serum chemistry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Male and female subjects between 18 and 70 years of age
  2. Oral ulcers that occurred at least monthly in the 6 month period prior to enrollment
  3. Had at least 2 oral ulcers in the 4 weeks prior to enrollment at baseline
  4. At least 3 oral ulcers during an ulcer flare
  5. Patients must be candidates for systemic therapy for the treatment of oral ulcers, those that are considered unsuitable for topical therapy alone based on severity of disease, or whose oral ulcers cannot be adequately controlled with topical therapy.
  6. Female premenopausal subjects must use one of the approved contraceptive options while taking apremilast and for at least 28 days after administration of the last dose of apremilast
  7. Patients are able and willing to provide written informed consent after the nature of the study is fully explained.
  8. No evidence of systemic disease

Exclusion Criteria

  1. Prior use of apremilast.
  2. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
  3. Having received concomitant immune modulating therapy 12 weeks prior to enrollment, systemic steroids 6 weeks prior to enrollment or topical steroids within 4 weeks prior to enrollment.
  4. Pregnant women or breast-feeding mothers.
  5. Systemic or opportunistic fungal infection.
  6. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (tuberculosis and atypical mycobacterial disease, hepatitis B and C and herpes zoster, histoplasmosis, coccidiomycosis) or any major episode of infection requiring hospitalization or treatment with IV or oral antibiotics within 4 weeks of the screening phase.
  7. History of positive test for, or any clinical suspicion of, human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency.
  8. History of depression.
  9. Malignancy or history of malignancy, except for:

    a - treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; b - treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.

  10. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
  11. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
  12. Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
  13. Active substance abuse or a history of substance abuse within 6 months prior to screening.
  14. Presence of any of the following vitamin deficiencies - B1, B2, B6, B12, vitamin C, zinc, folate, iron.
  15. Celiac disease.
  16. Inflammatory Bowel Disease.
  17. Genital aphthous ulcers.
  18. Behçet's disease.
  19. History of positive patch test for allergic contact stomatitis.
  20. Positive anti-endomysial or anti-gliadin antibodies.
  21. A diagnosis of uveitis (current or previous).
  22. Erythema nodosum-like lesions (current or previous).
  23. An established diagnosis of a systemic disease (SLE, Reiter's, Sweet's and MAGIC syndrome).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690544


Locations
Layout table for location information
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Celgene
Investigators
Layout table for investigator information
Principal Investigator: Alison J Bruce Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: Alison J. Bruce, Principle Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03690544    
Other Study ID Numbers: 18-002914
First Posted: October 1, 2018    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomatitis
Stomatitis, Aphthous
Mouth Diseases
Stomatognathic Diseases
Apremilast
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents